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Abstract We have subcloned and expressed the N-terminal
portion of the recently sequenced metabotropic GABA receptor,
GABABR1a. This region of the receptor contains a complement
protein-like amino acid sequence. The purified 140-residue
recombinant protein fragment was soluble and stable. Mass
spectrometry indicated formation of four disulfide bonds, as
expected if two complement protein modules (CPs, also known as
SCRs, Sushi domains) are formed. The circular dichroism
spectrum was unusual and characteristic of CPs. Differential
scanning calorimetry demonstrated a melting point (64‡C), and
total enthalpy commensurate with two fully folded domains. We
thus conclude that the 1a subtype of the GABAB receptor, but
not the 1b subtype, contains a pair of CPs and we present a three-
dimensional model of this region.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The GABAB receptor (GABABr) has seven trans-mem-
brane helices [1], is guanine nucleotide binding protein-linked,
and is stimulated selectively by baclofen [2]. Activation of
GABABr results in a range of profound and relatively long-
term metabolic e¡ects (reviewed in [3]). Baclofen is used to
treat spasticity arising from multiple sclerosis or spinal injury
and GABAB agonists may have applications in absence epi-
lepsy, anxiety, depression and cognitive dysfunction [4].
Recently, the amino acid sequences of two subtypes of the
rat GABABr were determined using expression cloning [1].
Subtypes 1a and 1b represent alternatively spliced forms and
are identical with the exception of a 130-residue extension at
the extracellular N-terminus of GABABr1a, immediately fol-
lowing the putative signalling sequence. Interest has so far
focused on similarities in amino acid sequence between the
extracellular regions of GABABr1 and the metabotropic glu-
tamate receptors and bacterial amino-acid transport proteins.
However, signi¢cant homology with these proteins does not
extend to the N-terminal portion of GABABr1a. The authors
referred to, but did not comment upon a ‘weak homology’
between GABABr1a and complement receptor type 1 (CR1)
[1]. By considering only the N-terminal extension of subtype
1a, we have noticed a previously unreported and striking ho-
mology with the family of proteins known as the regulators of
complement activation, of which CR1 is a member (reviewed
in [5]). Speci¢cally, residues 11^134 appear to comprise a tan-
dem pair of consensus sequences for the ‘CP’ module (also
called SCR and Sushi domain) (Fig. 1).
The occurrence of CPs is limited mainly but not exclusively
to proteins of the complement, immune and clotting systems
where they engage in speci¢c protein/protein recognition
events. In general, CPs located towards the N-terminus of
receptors are directly involved in ligand binding (e.g. [6^9]).
The putative CPs at the N-terminus of GABABr1a could
therefore be involved in the recognition of an as yet unidenti-
¢ed ligand. Thus we have set out to provide experimental
evidence that this sequence does indeed fold into CP modules.
2. Materials and methods
Based on the published sequence of the rat GABABR1a gene (ac-
cession no. Y10369), we devised a reverse transcriptase-polymerase
chain reaction (PCR) strategy to subclone into a Pichia pastoris ex-
pression vector, the portion of the N-terminal extracellular region of
the GABABr1a gene product that has sequence homology with CPs.
This region, in the published sequence, begins with the 11th residue
following the putative signal peptide cleavage site and extends for 134
residues (Fig. 1). We designed two oligonucleotides that would allow
us to PCR-amplify and subclone the sequence corresponding to res-
idues 8^144 of the rat GABABr1a gene (where residue 1 is the Gly
residue immediately following the proposed signal peptide sequence).
The 5P PCR primer was designed to include an EcoRI restriction site.
The opposing £anking primer incorporated a NotI restriction site
following two sequential stop codons. The template DNA used for
the PCR ampli¢cation was cDNA, prepared from a mixture of
poly(A) and total mRNA from adult rat brain, provided by Dr. Diane
Lipscombe (Department of Neuroscience, Brown University). The
ampli¢cation was performed using the Boehringer Mannheim Expand
High Fidelity PCR System according to the manufacturer’s recom-
mendations. A band of the appropriate mobility was observed follow-
ing electrophoresis in 1.5% agarose. The resulting PCR product was
treated with EcoRI and NotI. Ligation to pPICZK vector DNA (In-
vitrogen) similarly restricted with EcoRI and NotI (provided by Dr.
Nick Mullin, University of Edinburgh) was performed under standard
conditions.
Top10FP cells were transformed with the ligation product by elec-
troporation and Zeocin-resistant transformants were selected on low-
salt LB plates containing Zeocin according to the Invitrogen protocol.
Several transformants were isolated and checked for insert sequence
by PCR. The expected vector insert DNA sequence was con¢rmed in
one of the clones by sequencing both strands.
Midi-preps were prepared of the shuttle vector containing the insert
and 20 Wg of the resulting DNA was linearised with SacI. Transfor-
mation into P. pastoris strain KM71 (MutS) was accomplished by
electroporationn. Candidate Zeocin-resistant transformants were pu-
ri¢ed by re-streaking onto Zeocin-containing plates, then tested for
protein expression. Single colonies were used to inoculate 20 ml bu¡-
ered minimal medium with glycerol as sole carbon source (BMG) in a
50-ml tube (see the Invitrogen Expression manual). After overnight
growth in a 30‡C shaking incubator, cells were harvested by centrifu-
gation and resuspended in 4 ml of the induction medium containing
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methanol (0.5% ¢nal concentration) in place of glycerol as sole carbon
source (BMM). The induced cultures were incubated for two days in a
30‡C shaking incubator and additional methanol was added after 24 h
to maintain a ¢nal concentration of 0.5%. Subsequently, the super-
natant was collected and the protein in the supernatant precipitated
with 10% trichloroacetic acid (TCA; ¢nal concentration), pelleted by
centrifugation and washed twice with a 1:1 mixture of ethanol/ether.
The ¢nal protein pellet was analysed by SDS-PAGE for protein ex-
pression. Of twenty isolates tested, all expressed a protein of the
appropriate molecular weight not found in control transformed cul-
tures or in control untransformed cultures. One isolate, designated
K8, exhibited a much higher level of protein production than the
remaining transformants.
Larger cultures of K8 were prepared and the culture medium from
these growths was used after 2^3 days of methanol induction to pre-
pare protein samples on a larger scale. As a ¢rst step in puri¢cation,
the culture medium was concentrated V20-fold by ultra¢ltration
(Amicon YM3000). The resulting concentrate contains protein at a
concentration of V3 mg/ml (Bradford assay). N-terminal sequencing
was performed on a protein sample that was TCA-precipitated from
an ultra¢ltration concentrate and subjected to SDS-PAGE. The SDS-
PAGE-fractionated protein was transferred from the gel to a PVDF
membrane by electrophoresis and stained with Coomassie Blue. Fol-
lowing air-drying, the section of membrane containing the major band
of stained protein was excised.
For further puri¢cation, samples of protein concentrate were ap-
plied to an analytical C18 RP-HPLC column and eluted with a gra-
dient of acetonitrile (containing 0.1% tri£uoracetic acid). Most of the
protein eluted at an acetonitrile concentration of V46%. The eluate
containing the major fraction was collected and solvent was removed
by evaporation.
N-terminal sequencing was conducted by Dr Andrew Cronshaw,
Department of Biochemistry, University of Edinburgh. Electrospray
ion mass spectrometry (MS) was kindly performed on a Micromass
Platform II instrument by Joanne O’Leary, Department of Chemistry,
University of Edinburgh. Measurements of circular dichroism (CD)
were made using a Jasco-600 spectropolarimeter (Japan Spectroscopic
Co., Tokyo) with cylindrical quartz cell of pathlength 0.5 cm at the
BBSRC-funded centre for CD at the University of Stirling with the
kind assistance of Dr Sharon Kelly and Professor Nick Price. The
protein concentration was 0.03 mM. Di¡erential scanning calorimetry
(DSC) studies were conducted on an MC-2 (Microcal Inc., North-
ampton, MA, USA), at the BBSRC-funded UK Microcalorimetry
Facility in the Department of Chemistry, University of Glasgow
with the kind assistance of Professor Alan Cooper. The cell volume
was 1.5 ml, rate of heating was 1‡C min31, and excess pressure was
kept equal to 80 bar. The protein concentration was 0.1 mM. The
partial molar heat capacity and melting curve were analysed using
standard procedures [10]. The data were processed using the software
ORIGIN 2 (Microcal Inc.). Three-dimensional molecular models were
constructed within the program MODELLER [11] using homology to
the known single and double CP-module structures.
3. Results and discussion
Fig. 1 shows the sequences 11^76 and 77^134 of GA-
BABR1a aligned with the third and fourth CPs from Vaccinia
virus complement control protein (VCP) and CPs 15 and 16
from human factor H. Structures of both these pairs have
been solved [12,13]. Also included are a pair of CP-like se-
quences found in the mouse brain protein SEZ-6 [14]. A sche-
matic summary of secondary structure is shown along with
the consensus sequence. The overall sequence identity between
VCP module 3, a typical CP of known three-dimensional
structure, and GABABR1aV11^76 is 15% while sequence
similarity is 23%. Equivalent values for GABABR1aV
77^134 are 22% and 37%, respectively. The ¢rst sequence is
characterised by an insertion between putative strands two
and three. This is called the hypervariable loop and is fre-
quently a site for insertions; however, the GABABR1aV11^
76 sequence carries a longer insertion at this position than has
been observed in any other known CP-like sequence. The
second sequence is unusual (but not exceptional) in having
no prolines between putative strands one and two. In a multi-
ple sequence alignment involving CP sequences from s 50
distinct proteins (Barlow and Coulson, unpublished data),
the second GABABr CP-like sequence clusters with the 6th,
13th, 20th and 27th CP of CR1 and the 4th CP of CR2 while
the ¢rst CP-like sequence was an outlier. The two GABABr
CP-like sequences are joined by a linking sequence of four
amino acid residues which is typical for tandemly arranged
CPs. Thus, the sequence of this region is suggestive of the
presence of CPs in GABABr1a. However, neither of the se-
quences is typical ^ therefore it was necessary to obtain ex-
perimental proof that the CP fold is indeed adopted by ex-
pressing and analysing the relevant fragment.
The N-terminal sequence of the recombinantly expressed
protein was determined to be EAEFATSEG. This corre-
sponds to the expected sequence of ATSEG preceded by
four extra residues. The EF sequence is encoded by the EcoRI
site that was engineered into the 5P-end of the initial PCR
product. The N-terminal EA sequence is derived from the
pPICZK vector and is due to incomplete signal cleavage.
The molecular weight of the resulting protein was determined
by MS. The major protein in the sample had a mass of
15 628.7 Da ^ consistent with the expected size of the target
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Fig. 1. Primary and secondary structure. The two putative CP sequences from GABABR1a are shown aligned with a pair of CP-like sequences
found in SEZ-6. Also included in the alignment are the 3rd and 4th CPs from Vaccinia complement control protein (VCP) and the 15th and
16th from human factor H. Solution structures of both these pairs have been solved by NMR. A schematic summary of secondary structure
(numbered arrows and boxes indicate approximate extent of L-strands) as determined (for VCP3 and 4 and for fH15 and 16), is shown along
with the consensus sequence (de¢ned as residues which occur at a particular position in more than 80 out of a sample of 140 CP-module se-
quences).
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GABABR1a-derived fragment, i.e. a 140 amino acid protein
with the sequence EAEFATSEGCQIIHPPWEGGIRYRGL-
TRDQVKAINFLPVDYEIEYVCRGEREVVGPKVRKCL-
ANGSWTDMDTPSRCVRICSKSYLTLENGKVFLTGGD-
LPALDGARVEFRCDPDFHLVG SSRSVCSQGQWSTPK-
PHCQVN.
If all eight cysteines were in the reduced form, the expected
mass for this polypeptide sequence would be 15 636.7 (average
molecular weight). The observed mass of 15 628.7 corresponds
to the expected mass if all 8 cysteines are in the disulphide
form, as would be expected if two CPs are formed. In addition
to the major secreted protein, a minor protein of apparent
mass V20 kDa is also secreted into the medium (Fig. 2).
This second protein remains a minor component after 2^3
days of induction. It was found to have the same N-terminal
sequence as the major fraction. The higher mass is presumably
due to glycosylation as there is one N-linked glycosylation
consensus Asn residue within the subcloned region. Treatment
of the mixture with Endo-H resulted in loss of this band (not
shown). Some other variants observed by MS following longer
induction periods (5^6 days) include proteins lacking either
the ¢rst 2, 4, or 6 N-terminal residues of the major protein
species described above.
Fig. 3 shows CD spectra collected on a sample of the GA-
BABr1a fragment. Also shown are CD spectra of 120-residue
fragments of: complement control receptor type 1 (CR1) en-
compassing the 15th and 16th CP modules, provided by Dr.
M. Krych and Professor J. Atkinson of the Washington Uni-
versity School of Medicine, St. Louis, MO; and decay accel-
erating factor (DAF) modules 3 and 4 (supplied by R. Powell,
University of Reading). The pro¢les at 20‡C are highly un-
usual in that they display a large positive ellipticity in the
range 220^260 nm. However, they are very similar to one
another. Also shown in Fig. 3 are a series of CD spectra for
the GABABr1a fragment collected over a range of temper-
atures (20^70‡C). The positive maximum decreases as the tem-
perature is raised, and the spectra become characteristic of
random coil above 60^65‡C. Other CP-module pairs display
a roughly similar behaviour, according to CD, upon denatu-
ration by temperature or guanidine HCl. It was also observed
(not shown) that disruption of the disulphide bonds causes
loss of the positive maximum. Thus, these plots provide
very compelling evidence for the existence of folded CP-mod-
ules in the GABABr1a fragment.
Fig. 4 shows the pro¢le obtained from a DSC study. The
value of Cp for the folded protein was 0.3 cal (g ‡C)31 which
falls in the range of folded globular proteins, 0.28 þ 0.55 cal
(g ‡C)31 [10]. The protein aggregated immediately after melt-
ing and therefore values of vCp were not calculated [15]. The
melting temperature is relatively high (64‡C), and is consistent
with a protein that has a stable and well-de¢ned tertiary struc-
ture. This observation is consistent with the melting pro¢les
obtained by CD in Fig. 3. The value of calorimetric enthalpy
(90 kcal/mol) is consistent with values obtained for other
globular proteins of a similar size. It is somewhat lower
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Fig. 2. Puri¢cation of GABABr1a N-terminal fragment. A: The re-
sults of polyacrylamide gel electrophoresis (15% acrylamide) run
under denaturing and reducing conditions and stained with Coo-
massie Blue. Lanes 1^3: 20 Wl loaded derives from 500 Wl of cell
media following TCA precipitation, 6, 5 and 4 days post-induction.
B: Lanes 4 and 5: two peaks from a reverse phase HPLC (C18)
run illustrating resolution of larger, glycosylated (lane 4) from non-
glycosylated protein (lane 5).
Fig. 3. CD spectra of CR1V15,16 at pH 6.0 and 20‡C; DAFV3,4
under the same conditions; and the GABABr1a N-terminal frag-
ment at pH 8.0 over a range of temperatures from 20 to 70‡C as in-
dicated by the numbers on the plot. The protein concentration was
0.03 mM and the bu¡er was 25 mM sodium phosphate for all ex-
periments.
Fig. 4. Temperature dependence of partial molar heat capacity of
GABABr1a N-terminal fragment at pH 8.0, 25 mM sodium phos-
phate, the protein concentration was 0.1 mM. Experimental curves
are shown by the solid line, and the ¢tted curve (using ORIGIN)
by a dotted line.
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than the calorimetric enthalpy obtained for CR1V15,16 (120
kcal/mol, data not shown) but much higher than would be
expected for a single CP. The enthalpy calculated from the
van ’t Ho¡ equation is 67 kcal/mol which is lower than the
calorimetric enthalpy. This implies that the protein does not
represent a single cooperative system. Rather this situation
[16] is consistent with independent, or weakly interdependent,
units which have very similar melting temperatures. There-
fore, this experiment supports the presence of two similarly-
folded modules.
Taken together, the sequence alignment, CD and DSC pro-
vide strong support for the hypothesis that this sequence folds
into a tandem pair of CPs. Fig. 5 shows the outcome of a
homology modelling exercise based on the sequence alignment
of Fig. 1. The model was assessed using WHATIF [17] and
PROCHECK [18]. For each of the checks performed by
WHATIF the quality of the model was comparable to that
obtained for the calculated structure of VCP3,4. The overall
G factor for the model obtained from PROCHECK, which is
a carefully weighted average of all the stereochemical analyses
performed by PROCHECK, was 30.46. Structures are con-
sidered ‘normal’ if they have an overall G value greater than
30.50 [18].
Complement protein modules, which are frequently N-gly-
cosylated, are globular in structure with a compact hydropho-
bic core containing side-chains of highly conserved residues,
wrapped in L-sheets whose short strands lie approximately
parallel with the long axis of the module (reviewed in [19]).
Two disulphide linkages stabilise this framework-like struc-
ture while loops and turns serve as sites for insertions. A
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Fig. 5. Model of the N-terminus of GABABR1a. A: MOLSCRIPT [20] representation. The invariant Trp residues are shown, potential N-gly-
cosylation sites and the hypervariable loops are indicated. Strands are numbered as in Fig. 1. B: Accessible surface calculation and imaging
(same orientation as the previous diagram) done using GRASP [21]. The hypervariable loops are coloured purple in the ¢rst module and green
in the second module.
E. Hawrot et al./FEBS Letters 432 (1998) 103^108106
prominent loop region of low sequence conservation pro-
trudes laterally to the long axis and is called the hypervariable
loop. The N-terminal residue is located at one extremity of the
long axis, the C-terminal residue at the other. A MOL-
SCRIPT [20] representation of the model for GABABr1a is
shown with strands numbered as in Fig. 1. Also shown is a
solvent accessible surface (GRASP [21]). The three-dimension-
al model reveals a highly extended structure with a large sur-
face area-to-volume ratio. Particularly prominent is the inser-
tion between strands 2 and 3 in the hypervariable region of
the ¢rst module which results in a large loop close to the N-
terminus. This region has been implicated in binding speci¢c-
ity in the case of other CPs. A potential N-glycosylation site
lies at AsnV7 which is within a 10-residue N-terminal exten-
sion (not modelled), and a second N-glycosylation site ocurs
at AsnV67 which is nearby in the loop between strands 6 and
7. The observed glycosylation of the recombinant GABABr
fragment is consistent with the surface exposure of this site in
the model.
A range of speci¢c protein/protein recognition events, both
at the cell surface and in the serum are mediated by CPs.
Amongst the known or suspected ligands for these function-
ally diverse modules are: key proteins of the complement
system; interferon-K and interleukin-15; CD23; CD97; vita-
min K-dependent protein S; heparin; viruses including the
Epstein-Barr virus, the measles virus, and echovirus; and bac-
terial proteins (see [13] for references). CP-like sequences have
been identi¢ed so far in more than 50 distinct proteins from
sources such as plasma, the surface of many cell types, the
spermatozoon acrosomal matrix (e.g. [22]), the retina [23] and
the CNS [14,24^26].
The discovery of CPs in a GABAB receptor is entirely novel
and unexpected. Their location at the N-terminal extremity of
the protein indicates that they are probably exposed to the
extracellular environment. In general, where CPs occur to-
wards the N-terminus of cell-surface receptors they are in-
volved in ligand recognition rather than playing a purely
structural role ^ this has been shown for the N-terminal two
modules of CR2 [6], the N-terminal three modules of CR1 [7],
the N-terminal two modules of MCP (for measles virus) [9]
and CPs 2, 3 and 4 of DAF [8]. The two CPs of GABABr1a
are the only features that distinguish it from GABABr1b [1].
GABABr1a and GABABr1b have distinct cellular localisa-
tions within the brain suggestive of di¡erent physiological
roles [27]. It thus appears very likely indeed that the two
GABABr1a CPs are involved in molecular recognition and
furthermore that important physiological functions are medi-
ated via ligation of the CPs. It is unlikely that the ligand is
GABA or its analogues since the pharmacological pro¢les of
the two subtypes are nearly identical with regard to estab-
lished GABABr agonists and antagonists [1]. Although the
N-terminal regions of the metabotropic glutamate receptors
exhibit some similarity to the N-terminus of GABABr1a [1], it
is not possible that these much shorter regions form CPs.
Precedents do exist for the occurrence of putative CP-mod-
ules in CNS proteins. For example, SEZ-6 is a mouse mem-
brane protein of unknown function which contains ¢ve CP-
like sequences, and whose expression is increased by the ac-
tion of convulsant drugs [14]. The chondroitin sulfate proteo-
glycans brevican and neurocan each contain a single CP-like
sequence [25,26]. Brevican is found on astrocytes, while neuro-
can is neurone-speci¢c. Both proteins are involved in develop-
ment, and neurocan is known to bind to tenascin-C possibly
via its CP-like sequence [28]. The Hikaru genki protein is a
Drosophila protein containing CP-like sequences [26] that is
secreted from pre-synaptic terminals into the synaptic cleft at
critical stages during development and is thought to be in-
volved in formation of functional neural circuits [29]. It seems,
therefore, that putative CNS CPs are involved in binding
events critical for both normal and abnormal synaptic func-
tion and development. GABABR1a is known to have rele-
vance to epilepsy: a decrease in inhibitory neurotransmission
levels involving GABABr has been reported in animal models
of temporal lobe epilepsy [30], while an increased level of
GABAB-mediated transmission may be involved in absence
seizures [31] ; the human gene for GABABr1 has been mapped
to Chr 6p21.3 which is in the vicinity of the locus for juvenile
myoclonic epilepsy [32]. Thus the CPs of GABABr1a might
represent extremely important new drug targets.
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